Topics

Gliomas | Diagnosis | Proton emission tomography

Home > Publications > Topics > Gliomas > Diagnosis > Proton emission tomography

Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M.
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Lancet Oncol. 2024 Jan 2;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. PMID: 38181810. Review, Guidelines˰ ˍ

Yu P, Wang Y, Su F, Chen Y.
Comparing [18F]FET PET and [18F]FDOPA PET for glioma recurrence diagnosis: a systematic review and meta-analysis.
Front Oncol. 2024 Jan 10;13:1346951. doi: 10.3389/fonc.2023.1346951. PMID: 38269019. Review, Meta-analysis. ˍ

Zinsz A, Pouget C, Rech F, Taillandier L, Blonski M, Amlal S, Imbert L, Zaragori T, Verger A.
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions.
Eur J Nucl Med Mol Imaging. 2024 Apr 19. doi: 10.1007/s00259-024-06720-y. PMID: 38637354. Observational study˰ ˍ

McBriar JD, Shafiian N, Scharf S, Boockvar JA, Wernicke AG.
Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future.
Clin Nucl Med. 2024 Jul 3. doi: 10.1097/RLU.0000000000005365. PMID: 38968568. Review˰ ˍ

Galldiks N, Lohmann P, Friedrich M, Werner JM, Stetter I, Wollring MM, Ceccon G, Stegmayr C, Krause S, Fink GR, Law I, Langen KJ, Tonn JC.
PET imaging of gliomas: Status quo and quo vadis?
Neuro Oncol. 2024 Jul 6:noae078. doi: 10.1093/neuonc/noae078. PMID: 38970818. Review˰ ˍ

Robert JA, Leclerc A, Ducloie M, Emery E, Agostini D, Vigne J.
Contribution of [¹⁸F]FET PET in the Management of Gliomas, from Diagnosis to Follow-Up: A Review.
Pharmaceuticals (Basel). 2024 Sep 18;17(9):1228. doi: 10.3390/ph17091228. PMID: 39338390. Review. ˍ

Azam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I, Skjøth-Rasmussen J, Kjaer A.
Prospective phase II trial of [⁶⁸Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy.
EJNMMI Res. 2024 Oct 29;14(1):100. doi: 10.1186/s13550-024-01164-9. PMID: 39472354. Interventional study. ˍ

Pełka K, Koczyk K, Koperski L, Dziedzic T, Nowak A, Królicki L, Kunert P, Kunikowska J.
Imply on diagnosis and early prognosis of preoperative [⁶⁸Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin.
Sci Rep. 2025 Jan 2;15(1):214. doi: 10.1038/s41598-024-84036-5. PMID: 39747932. Interventional study. ˍ

Li Y, Wang R, Chen J, Zhu Z, Wang Y, Ma W.
⁶⁸Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study.
EJNMMI Res. 2025 Jan 17;15(1):6. doi: 10.1186/s13550-025-01198-7. PMID: 39821814. Interventional study. ˍ